公开(公告)号：US20250009666A1

公开(公告)日：2025-01-09

申请号：US18760369

申请日：2024-07-01

Applicant: Luisam Tarrats

Inventor： Luisam Tarrats

IPC: A61K9/20 ,  A61K31/351 ,  A61K31/4045 ,  A61K31/422 ,  A61K31/4468 ,  A61K31/455 ,  A61K31/485 ,  A61K31/565 ,  A61K31/58 ,  A61K38/09 ,  A61K38/095 ,  A61K38/23

Abstract: Disclosed are rapidly dissolving salt tablet compositions. Methods for using the rapidly dissolving salt tablets for preparation of isotonic saline solutions for use in nasal irrigation or cleansing are provided.

公开(公告)号：US20240342247A1

公开(公告)日：2024-10-17

申请号：US18577369

申请日：2022-07-08

Applicant: GILA THERAPEUTICS, INC.

Inventor： Thomas VASICEK

IPC: A61K38/22 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28

CPC classification number: A61K38/22 ,  A61K38/2264 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28

Abstract: The invention provides compositions and methods for inducing activating a neural receptor. The compositions include a metabolic hormone, which can be used to provide treatment for an addiction or mood disorder in a subject.

公开(公告)号：US20240238415A1

公开(公告)日：2024-07-18

申请号：US18559261

申请日：2022-05-04

Applicant: Baylor College of Medicine

Inventor： Brendan LEE

IPC: A61K39/395 ,  A61K31/663 ,  A61K38/23 ,  A61K38/29 ,  A61K47/64 ,  A61P19/08 ,  C07K16/22

CPC classification number: A61K39/3955 ,  A61K31/663 ,  A61K38/23 ,  A61K38/29 ,  A61K47/645 ,  A61P19/08 ,  C07K16/22 ,  C07K2317/21

Abstract: The present disclosure provides methods for treating and improving moderate-to-severe osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGFβ).

公开(公告)号：US20230310471A1

公开(公告)日：2023-10-05

申请号：US17718673

申请日：2022-04-12

Applicant: Alan Neil Glazier

Inventor： Alan Neil Glazier

IPC: A61K31/69 ,  A61K31/537 ,  A61K39/395 ,  A61K31/015 ,  A61K31/352 ,  A61K31/05 ,  A61K38/39 ,  A61K38/22 ,  A61K38/26 ,  A61K38/25 ,  A61K38/29 ,  A61K38/23 ,  A61K31/27 ,  A61K31/445 ,  A61K31/13 ,  A61K31/55 ,  A61K31/439 ,  A61K31/4178 ,  A61K31/40

CPC classification number: A61K31/69 ,  A61K31/537 ,  A61K39/3955 ,  A61K31/015 ,  A61K31/352 ,  A61K31/05 ,  A61K38/39 ,  A61K38/2235 ,  A61K38/26 ,  A61K38/25 ,  A61K38/2278 ,  A61K38/29 ,  A61K38/225 ,  A61K38/23 ,  A61K38/2228 ,  A61K38/22 ,  A61K31/27 ,  A61K31/445 ,  A61K31/13 ,  A61K31/55 ,  A61K31/439 ,  A61K31/4178 ,  A61K31/40

Abstract: Disclosed herein are methods, devices, and systems for treating lens protein aggregation diseases by reducing the formation of proteins responsible for crowding, compacting, and/or causing increased internal lens pressure. Specifically disclosed herein are ophthalmologic compositions comprising one or more agents that regulate water, sodium, and/or calcium ion transport and/or storage through lens fiber cell channels, and/or reduce the formation and/or production of proteins responsible for crowding, compacting, and/or causing increased internal lens pressure.

公开(公告)号：US20230181693A1

公开(公告)日：2023-06-15

申请号：US17969971

申请日：2022-10-20

Applicant: NEPSONE EHF

Inventor： Birkir SVEINSSON

IPC: A61K38/22 ,  A61P17/06 ,  A61K9/00 ,  A61P17/02 ,  A61K38/23

CPC classification number: A61K38/225 ,  A61K9/0014 ,  A61K38/23 ,  A61P17/02 ,  A61P17/06

Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the prepsoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.

公开(公告)号：US20230055912A1

公开(公告)日：2023-02-23

申请号：US17816084

申请日：2022-07-29

Applicant: Regeneron Pharmaceuticals, Inc. ,  The Royal Institution for the Advancement of Learning / McGill University

Inventor： Jonas Bovijn ,  Okukayode Sosina ,  Sirui Zhou ,  Luca Andrea Lotta ,  Aris Baras ,  Brent Richards

IPC: C12N15/113 ,  C12Q1/6883 ,  A61K31/663 ,  A61K31/675 ,  A61K38/23 ,  A61K38/29 ,  C07K16/28 ,  A61K31/565 ,  A61K31/57 ,  A61K31/4535

Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.

公开(公告)号：US11219697B2

公开(公告)日：2022-01-11

申请号：US16623740

申请日：2018-07-13

Applicant: The Regents of the University of California ,  UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： Ichiro Nishimura ,  Akishige Hokugo ,  Kenzo Morinaga ,  Charles E. McKenna ,  Boris A Kashemirov ,  Eric T. Richard

IPC: A61K49/00 ,  A61K47/54 ,  A61K47/64 ,  A61K9/00 ,  A61K38/23 ,  A61K38/29

Abstract: In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). In certain embodiments the “probes” comprise cleavable fluorophore-quencher pair linked by a cathepsin K (or other protease) peptide substrate and tethered to a bisphosphonate. Unlike existing probes that are cleared within a few days in vivo, the probes described herein (e.g., OFS-1) allow for monitoring resorption over the course of longer time periods with a single dose.

公开(公告)号：US11013691B2

公开(公告)日：2021-05-25

申请号：US16529040

申请日：2019-08-01

Applicant: MannKind Corporation

Inventor： Karine Fabio ,  Joseph J. Guarneri ,  Kieran Curley ,  Marshall L. Grant ,  Andrea Leone-Bay

IPC: A61K38/12 ,  A61K9/16 ,  A61K38/095 ,  A61K9/00 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28 ,  A61K38/29 ,  A61K45/06 ,  A61K31/198 ,  A61K31/4172

Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

公开(公告)号：US10568835B2

公开(公告)日：2020-02-25

申请号：US14592205

申请日：2015-01-08

Applicant: SDG, INC.

Inventor： John R. Lau ,  W. Blair Geho

IPC: A61K9/127 ,  A61K38/28 ,  A61K38/23 ,  A61K31/4045 ,  A61K38/21 ,  A61K47/24

Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

公开(公告)号：US20200023083A1

公开(公告)日：2020-01-23

申请号：US16288655

申请日：2019-02-28

Applicant: DUKE UNIVERSITY

Inventor： Ashutosh Chilkoti

IPC: A61K49/14 ,  A61K49/00 ,  A61K39/44 ,  A61K38/45 ,  A61K38/44 ,  A61K38/23 ,  A61K38/22 ,  A61K38/17 ,  A61K38/16 ,  A61K38/10 ,  A61K38/08 ,  A61K31/704 ,  A61K47/64

Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.